Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Prof Jeremy Chataway
Department of Neuroinflammation
Prof Jeremy Chataway profile picture
  • Professor of Neurology
  • UCL Queen Square Institute of Neurology
  • Faculty of Brain Sciences

Ten Most Significant Publications

    1. Chataway J., De Angelis, F., Connick P., ....Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo controlled trial.The Lancet Neurology. doi:10.1016/S1474-4422(19) 30485-5.
    2. Palladino R., Marrie RA., Majeed A., and Chataway J. Evaluating the risk of Macrovascular Events and Mortality among people with Multiple Sclerosis in England. JAMA Neurology. doi:10.1001/jamaneurology.2020.0664.
    3. Chataway, J., Martin, K., Barrell, K., Sharrack, B., Stolt, P., Wraith, D., & for the ATX-MS 1467 Study Group. (2018). Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosisNeurology. doi:10.1212/WNL.0000000000005118
    4. Lynch, D. S., Wade, C., Paiva, A. R. B. D., John, N., Kinsella, J. A., Merwick, Á., . . . Chataway, J. (2018). Practical approach to the diagnosis of adult-onset leukodystrophies: An updated guide in the genomic era. Journal of Neurology, Neurosurgery and Psychiatry. doi:10.1136/jnnp-2018-319481
    5. Chan D, Binks S, Nicholas J, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality of life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomized, placebo-controlled trial. Lancet Neurology2017 16:591-600.
    6. Fox, R. J., & Chataway, J. (2017). Advancing trial design in progressive multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, 23 (12), 1573-1578. doi:10.1177/1352458517729768
    7. Ontaneda D, Fox R, Chataway J.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Lancet Neurology 2015 14: 208-23.
    8. Chataway, J.,Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C.R., Clegg, S., Nielsen, C., Fox, N.C., Wilkie, D., Nicholas, J.M., Calder, V.L., Greenwood, J., Frost, C. and Nicholas, R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014 383:2213-2221.
    9. Chataway, J., Porter, B., Riazi, A., Heaney, D., Watt, H., Hobart, J., & Thompson, A. (2006). Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. The Lancet Neurology, 5 (7), 565-571. doi:10.1016/S1474-4422(06)70450-1
    10. Sawcer, S., Jones, H. B., Feakes, R., Gray, J., Smalldon, N., Chataway, J., . . . Compston, D. A. S. (1996). A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics, 13, 464-468.
Research Themes
Research Summary

My research career is centred around clinical trials in neurology. The disease area is dominantly (though not exclusively) multiple sclerosis (MS), and within that, the less tractable secondary progressive stage, SPMS, which accounts for £4bn/year of health care expenditure. The work carried out has received international acclaim, as well as widespread media coverage.

I was Chief Investigator of the MS-STAT1 trial in SPMS  (Lancet 2014 and Lancet Neurology 2017) which demonstrated a reduction in brain atrophy (shrinkage) by 43%. It won the UK MS society 2014 research award category.

I lead the MS-SMART trial. It is a flagship study for the entire MS community, testing re-purposed compounds, in a multi-arm fashion. It has recently reported (Lancet Neurology 2020).

Currently I lead the HTA, UK and US MS Societies funded MS-STAT2 trial. This is a large phase 3 trial, building on MS-STAT1. We currently have 760/1050 patents randomised in 30 sites around the UK.

I work closely with the MRC Clinical Trials Unit, especially on Adaptive design

The Adult Leukodystrophy Group, which I co-funded, goes from strength to strength, and we are currently working with NHS England to commission a National Centre at NHNN/UCLH. Our recent review is: Practical approach to the diagnosis of adult-onset leukodystrophies: An updated guide in the genomic eraJournal of Neurology, Neurosurgery and Psychiatry. doi:10.1136/jnnp-2018-319481

Teaching Summary

  • My core activity is teaching UCL undergraduate medical students in formal lectures and at the bedside (weekly) in neurology.
  • I teach regularly on the UCL/UCLH MRes Translational Neurology and Clinical Neuroscience/Neurology courses. I am fully engaged, setting and marking questions to evaluate participant understanding.Feedback from these is in the very good to excellent range.
  • I was involved in setting the criteria for, and appointing  a statistician to teach and help MSc/PhD students. I am a member of the Library Committee with strong student educational mandate.
  • I set up a NeuroTrials course and teach three times/year on the International Data Monitoring Course hosted by MRC Trials Unit.
  • I review regularly for high impact journals: New England Journal of Medicine (NEJM), Lancet, Lancet Neurology.
  • I am a regular PhD examiner.

01-OCT-2018 Professor of Neurology Neuroinflammation UCL, United Kingdom
Some IRIS profile information is sourced from HR data as explained in our FAQ. Please report any queries concerning HR data shown on this page to hr-services@ucl.ac.uk.
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by